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ABSTRACT
Objectives: To determine the prevalence and quality
of antipsychotic prescribing for people with intellectual
disability (ID).
Design: A clinical audit of prescribing practice in the
context of a quality improvement programme. Practice
standards for audit were derived from relevant,
evidence-based guidelines, including NICE. Data were
mainly collected from the clinical records, but to
determine the clinical rationale for using antipsychotic
medication in individual cases, prescribers could also
be directly questioned.
Settings: 54 mental health services in the UK, which
were predominantly NHS Trusts.
Participants: Information on prescribing was
collected for 5654 people with ID.
Results: Almost two-thirds (64%) of the total sample
was prescribed antipsychotic medication, of whom
almost half (49%) had a schizophrenia spectrum or
affective disorder diagnosis, while a further third (36%)
exhibited behaviours recognised by NICE as potentially
legitimate targets for such treatment such as violence,
aggression or self-injury. With respect to screening for
potential side effects within the past year, 41% had a
documented measure of body weight (range across
participating services 18–100%), 32% blood pressure
(0–100%) and 37% blood glucose and blood lipids
(0–100%).
Conclusions: These data from mental health services
across the UK suggest that antipsychotic medications
are not widely used outside of licensed and/or
evidence-based indications in people with ID. However,
screening for side effects in those patients on
continuing antipsychotic medication was inconsistent
across the participating services and the possibility that
a small number of these services failed to meet basic
standards of care cannot be excluded.
INTRODUCTION
When dealing with adversity, people with an
intellectual disability (ID) may have less
resilience and poorer coping strategies, which
may manifest as ‘challenging behaviour’.1 It
has been estimated that between a quarter
and a third of people with ID across hospital
and community samples exhibit such behav-
iour1–3 and the lifetime prevalence may be as
high as 60%.4 Further, the prevalence of psy-
chiatric illness in people with ID is estimated
to be 8–15%.4 As the severity of ID increases,
it becomes more difﬁcult to diagnose mental
illness and determining the aetiology of any
Strengths and limitations of this study
▪ The large sample size suggests that our findings
are likely to be generalisable to all patients with
intellectual disability (ID) under the care of
mental health services in the UK.
▪ Data relating to the clinical rationale for prescrib-
ing antipsychotic medication were obtained from
clinical records and direct discussions with pre-
scribers; thus, we could assess the quality of
prescribing practice in this respect rather than
simply the quality of documentation.
▪ The focus of the study was the quality of anti-
psychotic prescribing practice in this clinical
population and not the broader clinical manage-
ment of challenging behaviour. Thus, we did not
collect data relating to the severity of challenging
behaviour(s) or whether other therapeutic strat-
egies to manage such behaviour(s) had been
tried before antipsychotic medication was
prescribed.
▪ Information on physical health checks and side
effect monitoring conducted in primary care
would have been missed if the details of these
assessments were not available in the mental
health clinical records. Thus, the extent of such
monitoring may be underestimated.
▪ Our findings relate only to those people with ID
under the care of mental health services and
cannot be extrapolated to those whose care is
delivered solely through primary care.
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behavioural disturbance is a matter for expert clinical
judgement. One treatment strategy for managing such
behaviour is antipsychotic medication, although the sup-
porting evidence is limited.5–7 In 2012, concerns regard-
ing the overuse of psychotropic medication in people
with ID and the harms this may cause were highlighted in
a national report prompted by a review of care at
Winterbourne View hospital.8 Subsequently, NICE1
recommended that antipsychotic medication should only
be considered for managing challenging behaviour in
people with learning disability where other interventions
have failed or the risk to the person or others is severe,
for example, because of violence, aggression or self-
injury. In the context of a quality improvement pro-
gramme (QIP), we report here on the prevalence and
quality of prescribing of psychotropic medication for
people with ID who are under the care of secondary
mental health services in the UK.
METHODS
The Prescribing Observatory for Mental Health
(POMH-UK) invited all National Health Service (NHS)
mental health Trusts and other healthcare organisations
in the UK to participate in an audit-based QIP focusing
on the prevalence and quality of prescribing of psycho-
tropic medication for people with ID. The methodology
of this QIP has been described elsewhere.9 Clinical
audits were conducted nationally in 2009, 2011 and
2015. We report here on the 2015 audit in which 54
mental health Trusts opted to participate.
Clinical practice standards for the QIP
Practice standards were initially derived from guidance
by Deb et al10 11 and these proved to be consistent with
practice recommendations in the NICE guidelines for
the management of challenging behaviour in people
with a learning disability1 and for the treatment of
schizophrenia.12 These practice standards were (1) the
indication for treatment with antipsychotic medication
should be documented in the clinical records; (2) the
continuing need for antipsychotic medication should be
reviewed at least once a year; and (3) side effects of anti-
psychotic medication should be reviewed at least once a
year, and this review should include assessment for the
presence of extrapyramidal side effects (EPS), and
screening for the four aspects of the metabolic syn-
drome: measures of blood pressure, obesity, glycaemic
control and plasma lipids.
QIP sample and data collected
Initially, the QIP focused on prescribing practice in rela-
tion to antipsychotic medication as there were evidence-
based sources from which standards could be derived.
For the most recent of the three QIP clinical audits, in
2015, participating Trusts were asked to include a
sample of people with ID, irrespective of whether they
were prescribed psychotropic medication or not. The
following data were collected on each eligible patient,
using a bespoke, standardised data collection tool con-
taining mandatory ﬁelds: patient identiﬁer (a code
known only to the Trust submitting data), age, gender,
ethnicity, clinical severity of ID, care setting, psychiatric
diagnoses,13 a diagnosis of epilepsy, details of prescribed
psychotropic medication and documented evidence of
medication review. With respect to those patients who
were prescribed antipsychotic medication, the clinical
rationales for such medication were collected along with
evidence of side effect monitoring to allow performance
against the audit standards to be measured. Audit data
were collected from the clinical records except for the
clinical reasons for prescribing antipsychotics for individ-
ual patients, which were to be obtained by discussion
with the doctors/prescribers in the clinical team.
Clinicians and clinical audit staff in each Trust collected
the audit data; ethical approval is not required for
audit-based quality improvement initiatives.
Data analysis
Data were submitted online using Formic software14 and
analysed using SPSS (SPSS statistics version V.21. IBM,
Chicago, Illinois, USA).
Individual Trust data sets were returned along with
any data cleaning queries, thus allowing the accuracy of
data entry to be checked.
Descriptive statistics were used to measure perform-
ance against the clinical practice standards in the total
national audit sample and in each participating Trust.
Benchmarking charts were produced to allow participat-
ing services to determine their absolute performance
against the standards and their relative performance
compared with other services. Each participating service
received a customised report which provided an analysis
of the audit results at national, Trust and within-Trust
clinical team level.
A binary logistic regression was performed to examine
the clinical factors associated with whether or not anti-
psychotic medication was prescribed. The analyses were
conducted in two stages. First, a series of univariable
analyses were performed to examine the associations
between being prescribed or not prescribed an anti-
psychotic and age, gender, ethnicity, clinical care setting,
ICD10 mental illness diagnostic categories and having a
diagnosis of epilepsy. The second stage jointly examined
associations with the outcome in a multivariable analysis.
To simplify the ﬁnal regression model, a backwards
selection procedure was performed to retain only the
statistically signiﬁcant variables. This involved omitting
non-signiﬁcant variables, one at a time, until only the
signiﬁcant variables remain.
RESULTS
Fifty-four Trusts submitted data for 5654 patients from
338 clinical teams. The median number of cases submit-
ted per Trust was 147 (range 10–469).
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Demographic and clinical characteristics of the sample
and the association between these and being prescribed
antipsychotic medication
The demographic and clinical characteristics of the
sample are shown in table 1. Data were submitted for
5654 patients: 3628 (64%) were prescribed antipsychotic
medication and 2080 (37%) were prescribed antidepres-
sant medication. In the total sample, 24% were pre-
scribed antipsychotic and antidepressant medication.
The multivariable analysis suggested that there was an
association between being prescribed an antipsychotic
and the following variables: being older than 25 years of
age, being cared for in a specialist ID inpatient setting
and having a diagnosis of a psychotic spectrum disorder
(ICD F20–F29), affective disorder (F30–F39), a disorder
of psychological development (F80–F89) or epilepsy.
The magnitude and direction of these associations are
shown in table 2. In the 3628 patients who were pre-
scribed antipsychotic medication, 3163 (87%) had
received such medication for more than a year.
Clinical rationale for antipsychotic treatment
The most common reasons for prescribing the current
antipsychotic medication in the total national sample
were psychotic disorder (41%), general agitation and
anxiety (41%), overt aggression (36%), threatening
behaviour (29%), self-harm and self-injurious behaviour
(19%) and obsessive behaviour (9%). Figure 1 shows the
proportions of patients prescribed and not prescribed
an antipsychotic and, in the former group, the propor-
tion who had a diagnosed schizophrenia spectrum or
affective disorder, exhibited a target symptom/behaviour
for antipsychotic treatment recognised by NICE or
neither of these clinical reasons. There were 593 (10%)
patients in this latter group, in whom the most common
diagnoses were disorders of psychological development
(ICD10 F80–F89, which includes autism; 40%), anxiety
spectrum disorders (ICD10 F40–F48; 20%) and behav-
ioural and emotional disorders with onset usually occur-
ring in childhood and adolescence (ICD10 F90–F98,
which includes ADHD; 9%), and the most common
target symptoms/behaviours prompting antipsychotic
treatment were agitation (57%), psychotic symptoms
(20%) and obsessive behaviours, including rituals
(13%).
Other medication prescribed
Thirty-seven per cent of the total national sample were
prescribed antidepressant medication, 54% of whom
had a diagnosis of depression or an anxiety spectrum
disorder. Other diagnoses in this group of patients
included disorders of psychological development
(ICD10 F80–F89: 26%), schizophrenia spectrum disor-
ders (F20–F29: 16%) and personality disorders (F60–
F69: 7%).
Table 1 Demographic and clinical characteristics of the
total patient sample (n=5654)
Key demographic and
clinical characteristics
Total national
sample, N=5654
Gender
Male 3445 (61%)
Ethnicity
White/White British 4590 (81%)
Black/Black British 194 (3%)
Asian/Asian British 273 (5%)
Mixed or other 597 (10%)
Age
Mean age in years (SD) 41.2 (15.3)
Age bands (years)
<16 44 (1%)
16–25 1004 (18%)
26–35 1262 (22%)
36–45 946 (17%)
46–55 1234 (22%)
56–65 785 (14%)
66 and over 379 (7%)
Severity of intellectual disability
Mild 2973 (53%)
Moderate 1531 (27%)
Severe 1150 (20%)
Current ICD10 diagnoses*
F00–F09 257 (5%)
F10–F19 138 (2%)
F20–F29 1005 (18%)
F30–F39 1332 (24%)
F40–F48 566 (10%)
F50–F59 29 (1%)
F60–F69 355 (6%)
F80–F89 1592 (28%)
F90–F98 378 (7%)
F99 11 (<1%)
Documented psychiatric diagnoses
None of the above 1376 (24%)
One of the above 3061 (54%)
Multiple 1217 (21%)
Epilepsy
Diagnosis documented 1328 (24%)
Clinical care setting
ID community team 4495 (80%)
Forensic inpatient 458 (8%)
Specialist ID inpatient 403 (7%)
General adult community team 209 (4%)
Continuing care/rehabilitation 66 (1%)
General adult acute ward 23 (<1%)
*ICD10 codes and diagnoses: F00–F09—organic, including
symptomatic, mental disorders; F10–F19—Mental and behavioural
disorders due to psychoactive substance use; F20–F29—
schizophrenia, schizotypal and delusional disorders; F30–F39—
mood (affective) disorders; F40–F48—neurotic, stress-related and
somatoform disorders; F50–F59—behavioural syndromes
associated with physiological disturbances and physical factors;
F60–F69—disorders of adult personality and behaviour; F80–F89
—disorders of psychological development; F90–F98—behavioural
and emotional disorders with onset occurring in childhood and
adolescence; F99—unspecified mental disorder.
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Forty-four per cent of the sample were prescribed anti-
convulsant medication (most commonly valproate, a
benzodiazepine or carbamazepine), 48% of whom had a
diagnosis of epilepsy. Ten per cent were prescribed anti-
cholinergic medication.
Performance against the practice standards
With respect to performance against the audit practice
standards, (1) the clinical indication for antipsychotic
medication was clear in 3537 (97%) cases; (2) of those
patients who had been prescribed antipsychotic treat-
ment for over 12 months (n=3163), 3066 (97%) had a
documented medication review in the last year, and of
those patients receiving drug treatments other than anti-
psychotics over the past 12 months (n=1334), 1191
(89%) had a documented medication review in the last
year; (3) with respect to those patients who had been
prescribed antipsychotic medication for more than
1 year, 1307 (41%) had a documented measure of body
weight (the range across participating services was 18–
100%), 1019 (32%; range 0–100%) of blood pressure,
1154 (37%; range 0–100%) of blood glucose and 1154
(37%; 0–100%) of blood lipids. In 2535 (80%; range
35–100%) of cases, there was a documented statement
about side effects, and in 294 (49%; range 12–100%),
there had been an assessment of potential movement
disorder induced by antipsychotic medication. As an
example, ﬁgure 2 shows the variation across services with
respect to monitoring of glycaemic control.
DISCUSSION
Prevalence of prescribing of antipsychotic medication and
the demographic and clinical characteristics of patients
who received such prescriptions
In our sample of people with ID who were in contact
with UK mental health services, just under two-thirds
(64%) were prescribed antipsychotic medication. This
Table 2 Multivariable analyses of demographic and clinical variables associated with people with intellectual disability being
prescribed antipsychotic medication
Variable Group OR (95% CI) p Value
Age (years) 14–25 1 <0.001
26–35 1.39 (1.16 to 1.67)
36–45 1.48 (1.21 to 1.81)
46–55 1.61 (1.33 to 1.95)
56–65 1.76 (1.42 to 2.20)
66 and older 2.24 (1.69 to 2.96)
Clinical care setting ID outpatient 1 0.001
ID inpatient 1.7 (1.32 to 2.18)
General adult 1.22 (0.87 to 1.71)
Forensic inpatient 1.04 (0.83 to 1.31)
Continuing care inpatient 1.17 (0.63 to 2.17)
F00–F19 No 1 <0.001
Yes 0.36 (0.26 to 0.48)
F20–F29 No 1 <0.001
Yes 19.2 (13.5 to 27.5)
F30–F39 No 1 <0.001
Yes 1.36 (1.15 to 1.61)
F40–F48 No 1 0.05
Yes 0.81 (0.67 to 1.00)
F80–89 No 1 <0.001
Yes 2.00 (1.70 to 2.37)
Any ICD10 mental illness diagnosis Yes 1 <0.001
No 0.63 (0.52 to 0.75)
Epilepsy No 1 <0.001
Yes 0.71 (0.62 to 0.81)
Figure 1 Prevalence and nature of antipsychotic prescribing
in people with intellectual disability in the total national sample
(TNS).
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proportion is considerably higher than the primary care
prevalence of 28% identiﬁed by Sheehan et al15 using
data obtained via The Health Improvement Network
and the 17% of patient days identiﬁed by Glover and
Williams16 using primary care data obtained via the
Clinical Practice Research Datalink (CPRD). This
marked difference from other UK samples may be at
least partly a consequence of the greater likelihood of
mental illness and/or challenging behaviour in those
people with ID who are in contact with mental health
services, compared with those in primary care. Indeed,
over three-quarters of our sample had at least one diag-
nosed mental illness, compared with fewer than one in
four in the primary care sample of Sheehan et al.15
There is, however, likely to be some overlap between
primary and secondary care samples as many people
who receive outpatient care from mental health services
receive their medication from their general practitioner.
The sample identiﬁed by Sheehan et al15 may, therefore,
have included patients who also received outpatient care
from mental health services.
Almost one-ﬁfth of our sample had a diagnosis of a
schizophrenia spectrum disorder and, compared with
those who did not have such a diagnosis, this subgroup
were 19 times more likely to be prescribed antipsychotic
medication. We also found that those people with a diag-
nosis of an affective disorder or a disorder of psycho-
logical development, including autism, were more likely
to be prescribed an antipsychotic, although the magni-
tude of the ORs, at 1.36 and 2.0, respectively, was consid-
erably more modest. While such prescribing partly
reﬂects the recognition of psychotic illness as an indica-
tion for antipsychotic medication in such a context, it
may also reﬂect that evidence-based guidelines have
identiﬁed a role for such medication in the manage-
ment of affective disorders and that published evidence
supports its use for the amelioration of some forms of
behavioural disturbance in patients with autistic spec-
trum disorders.17
We also found an association between antipsychotic
use and age, with those who were 65 years of age or
older being twice as likely to be prescribed an anti-
psychotic as those who were 25 years of age or younger.
This is consistent with the ﬁndings of Glover and
Williams16 and Sheehan et al.15 The reasons for this asso-
ciation are unclear, but potential explanations include
an age-related increase in the prevalence of challenging
behaviour and/or suboptimal processes for clinical
review of the medication, resulting in prescriptions
being continued unnecessarily.15
Most antipsychotic medicines have the potential to
lower the seizure threshold18 19 and the lower preva-
lence of prescribing in patients with epilepsy that we
found suggests that secondary care clinicians use these
medicines cautiously in this population. Antipsychotic
medicines are also associated with increased morbidity
and mortality in people with dementia20 and the ﬁnd-
ings of our logistic regression analyses suggest that clini-
cians generally avoid antipsychotics in people with ID
who also have a diagnosis of dementia. In primary care,
the reverse association has been reported.15
Clinical reasons for prescribing antipsychotic medication
The use of antipsychotic medicines to treat schizophre-
nia, bipolar disorder and depression is supported by
NICE guidelines for these conditions.12 21 22 It is also
common practice. Investigating psychotropic drug use in
a large US sample of adults with ID, Tsiouris et al23
found that half of such medication was prescribed for
the treatment of major psychiatric disorders. In addition,
the NICE guideline for the management of challenging
behaviour in people with a learning disability acknowl-
edges that antipsychotic medication may be indicated
where the risk to the person or others from such behav-
iour is severe, for example, because of violence, aggres-
sion or self-injury.1 Applying these recognised clinical
indications to our sample, over four-ﬁfths of those pre-
scribed an antipsychotic had one or more of these diag-
noses and/or challenging behaviours. Psychotic
symptoms (in the absence of a documented diagnosis of
psychotic illness) and obsessive behaviours (as part of
autistic spectrum disorders) accounted for a third of the
Figure 2 Proportion of people with intellectual disability prescribed antipsychotic medication for more than 1 year with
documented evidence in their clinical records of monitoring of glycaemic control in the last year.
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remainder. In a small minority of patients, antipsychotic
medication was prescribed for the management of agita-
tion. Such use may be appropriate as part of
de-escalation strategies in the prevention of violence.24
The clinical rationales for prescribing antipsychotic
medication in our audit sample were consistent with the
ﬁndings of a previous national audit9 and these data do
not support the claims that antipsychotic medications
are widely used outside of licensed and evidence-based
indications in people with ID,8 16 at least in those people
who are in contact with mental health services.
Our ﬁndings in this patient sample under the care of
mental health services contrast with those of Glover and
Williams16 who reported that potentially relevant indica-
tions for antipsychotic prescriptions were recorded in
only two-ﬁfths of cases in primary care. One potential
explanation for this difference is that our audit data on
the clinical rationale for antipsychotic treatment were
obtained on a patient-by-patient basis from prescribing
clinicians, augmenting the information extracted dir-
ectly from clinical records: our aim was to examine clin-
ical practice rather than clinical documentation.
Another possible explanation is that our sample of
patients were more likely to be systematically assessed
and to receive treatment from clinicians who were spe-
cialists in the diagnosis and management of mental
health and behavioural problems in people with ID.
Quality of prescribing practice related to antipsychotic
medication
In almost all patients in our sample, the reasons for pre-
scribing antipsychotic medication were clear and the medi-
cation had been clinically reviewed within the last year.
This suggests that decisions relating to the initiation of
antipsychotic medication were considered and that subse-
quent review of the impact of this intervention on target
symptoms was systematic. These ﬁndings are consistent
with those of a previous large UK audit.9 However, our
ﬁndings also suggest that side effect assessment was less
than assiduous, with just over a third of those patients who
had been prescribed antipsychotics for more than a year
having measures for body weight, blood pressure, blood
glucose and lipids all documented in the clinical records
and fewer than 1 in 10 having a formal assessment of
antipsychotic-induced movement disorder (EPS). There
was marked variation in the quality of assessment of side
effects across participating services and the possibility that
a small number of these services failed to meet basic stan-
dards of care cannot be excluded.
The proportion of patients assessed for metabolic side
effects was relatively low compared with community-
based patients with schizophrenia,25 26 perhaps partly
due to the additional challenges associated with phlebot-
omy in people with ID.
Other psychotropic medication prescribed
Over a third of patients in our sample were prescribed
antidepressant medication, half of whom had a diagnosis
of an affective or anxiety spectrum disorder. These diag-
noses are recognised as targets for such treatment. In
our sample of patients under the care of mental health
services, we found the prevalence of antidepressant use
to be double that identiﬁed by Glover and Williams16 in
a primary care sample, but the proportion of those pre-
scribed an antidepressant who had a relevant comorbid
disorder was similar. These ﬁndings suggest that antide-
pressants are commonly used for indications other than
mood and anxiety disorders in people with ID, and
indeed, a quarter of those patients in our sample who
were prescribed antidepressant medication had a diag-
nosed disorder of psychological development but no
mood or anxiety spectrum disorder. People with autism
commonly exhibit restrictive repetitive behaviours and
interests that are distressing and disruptive to function-
ing. Clinicians’ prescribing practice in this regard may
have been inﬂuenced by limited published evidence sup-
porting the effectiveness of SSRI antidepressants in
ameliorating obsessive–compulsive behaviour, aggression
and anxiety in adults with autism.27
We found that anticonvulsant medication, including
benzodiazepines, was prescribed for more than two-ﬁfths
of patients and that half of this subgroup had a diagno-
sis of epilepsy. We did not collect detailed data relating
to the clinical indications for this group of medicines,
but given that most are licensed for a number of differ-
ent indications, for example, valproate for bipolar dis-
order and benzodiazepines for anxiety and insomnia,
and that mood and anxiety disorders were prevalent in
our sample, these are the likely indications in the
remainder.
Almost 1 in 10 people in our sample were prescribed
anticholinergic medication, which may reﬂect a per-
ceived increased vulnerability to EPS in people with ID
who are prescribed antipsychotic medication. However,
anticholinergic medicines have established adverse
effects on cognition and it would seem prudent to min-
imise their use in people with ID.
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